4.6 Article

Relapsing neuromyelitis optica: long term history and clinical predictors of death

Journal

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 80, Issue 10, Pages 1162-1164

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp.2007.143529

Keywords

-

Funding

  1. Fondo de Investigaciones Sanitarios, Madrid, Spain [PI060070]
  2. U344 Inserm unit, Lyon, France

Ask authors/readers for more resources

Background: Relapsing neuromyelitis optica (RNMO) is an uncommon but devastating inflammatory disorder of the central nervous system. Long term history in a wide series of RNMO is required for better knowledge of the course of the disease and identification of patients at high risk of death. Methods: Clinical features of patients with RNMO (88 women/eight men) obtained from the geographic Caribbean database (Cuba and French West Indies) were used to determine the progression of disability and to identify clinical predictors of death. Results: Median age at onset of RNMO was 29.5 years (range 11-74). Median duration of disease was 9.5 years (1-40). Median relapse rate was 0.7 attack/patient/year (0.1-3). 66 patients experienced severe visual loss in at least one eye and 46 in both eyes. Median time from onset to unilateral and bilateral severe visual loss was 3 and 15 years, respectively. Median times to reach Kurtzke Disability Status Scale 3, 6 and 8 from onset of RNMO were 1, 8 and 22 years. There were 24 deaths (25%); within 5 years in 63% of cases. A higher attack frequency during the first year of disease (p = 0.009), blindness (p = 0.04) and sphincter signs at onset (p = 0.02) and lack of recovery of first attack (p = 0.003) were independently associated with a shorter time to death. Conclusion: RNMO is a very rapidly disabling disease affecting primarily young women. This study has identified clinical features that predict a poor outcome. These findings suggest that early and aggressive immunotherapy might be warranted in RNMO.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Correction Oncology

COGNITIVE AND BRAIN STRUCTURE CHANGES IN LONG-TERM SURVIVORS OF OLIGODENDROGLIOMA (vol 20, pg iii325, 2018)

N. Cayuela, E. Jaramillo-Jimenez, C. Majos, R. Velasco, T. Boget, F. Graus, J. Bruna, M. Simo

NEURO-ONCOLOGY (2021)

Article Clinical Neurology

Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis

Mickael Bonnan, Paul Money, Pauline Desblache, Raluca Marasescu, Lise-Marlene Puvilland, Stephanie Demasles, Camille Dahan, Elsa Krim, Alan Tucholka, Senan Doyle, Bruno Barroso

Summary: Recent studies have found chronic leptomeningeal enhancement in late-acquired FLAIR sequences of secondary progressive multiple sclerosis patients, which may lead to long-term cortical atrophy. A case report of spontaneously remitting meningeal uptake suggests that MRI may overlook the potential burden of previous regressive meningeal lesions.

NEUROLOGICAL SCIENCES (2021)

Article Clinical Neurology

Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome

Mar Petit-Pedrol, Mar Guasp, Thais Armangue, Cinzia Lavarino, Andres Morales La Madrid, Albert Saiz, Francesc Graus, Josep Dalmau

Summary: This study did not find GluD2 antibodies in a large cohort of patients with Opsoclonus-Myoclonus Syndrome (OMS), suggesting that these antibodies may not be biomarkers of OMS.

NEUROLOGY (2021)

Editorial Material Clinical Neurology

Towards a better recognition of paraneoplastic brainstem encephalitis

Francesc Graus

Summary: This study explores the clinical and immunological features of paraneoplastic cochleovestibulopathy which is associated with cancer.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Article Public, Environmental & Occupational Health

Hypoxemia and Cytokine Storm in COVID-19: Clinical Implications

Calixto Aguero-Martinez, Alina Gonzalez-Quevedo

Summary: Cytokine storm is a severe complication that can occur during the course of COVID-19, leading to excessive inflammatory response and ultimately resulting in tissue damage, organ failure, and death.

MEDICC REVIEW (2021)

Article Clinical Neurology

Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation

Mickael Bonnan, Emeline Berthelot, Philippe Cabre

Summary: Initial clinical manifestations of NMOSD may rarely overlap with MS. Fingolimod may trigger severe attacks in patients with NMOSD previously misdiagnosed as MS. Among high-risk Afro-Caribbean patients, the risk of misdiagnosed NMOSD in MS was estimated to be 1.9%. After initiation of fingolimod, relapses occurred within a month in five patients, with a shift to more severe disorder and large brain lesions noted.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Article Clinical Neurology

Proposal for the functional assessment of acute inflammatory neuropathy (FAAIN) in Guillain-Barre syndrome

Zurina Lestayo O'Farrill, Alina Gonzalez-Quevedo, Joel Gutierrez-Gil, Jose Luis Hernandez-Caceres, Vivian Sistach-Vega

Summary: A functional assessment tool for acute inflammatory neuropathies (FAAIN-GBS) was constructed and validated in this study. The tool consists of two subscales (extension and intensity) and the final score is obtained by averaging both dimensions. The validation results showed good internal consistency and validity, indicating its potential usefulness in neurological practice. However, further studies with larger populations are needed to improve this instrument.

NEUROLOGICAL RESEARCH (2022)

Article Public, Environmental & Occupational Health

A Shift in SARS-CoV-2 Omicron Variant's Entry Pathway Might Explain Different Clinical Outcomes

Calixto Machado-Curbelo, Joel Gutierrez-Gil, Alina Gonzalez-Quevedo

Summary: Globally, the omicron variant of SARS CoV-2 has caused a significant increase in COVID-19 cases with milder clinical symptoms and reduced hospitalizations. The omicron wave has spread faster than previous waves, completely replacing the delta variant within weeks, raising global concerns about pandemic control. The symptoms associated with omicron resemble those of the common cold and rarely include loss of taste and smell. Research suggests that direct invasion of the brainstem by SARS-CoV-2 through the olfactory nerves may explain the refractory respiratory distress syndrome seen in severe cases.

MEDICC REVIEW (2022)

Article Medicine, General & Internal

Susac Syndrome: Description of a Single-Centre Case Series

Sara Beca, Claudia Elera-Fitzcarrald, Albert Saiz, Sara Llufriu, Maria C. Cid, Bernardo Sanchez-Dalmau, Alfredo Adan, Gerard Espinosa

Summary: This study retrospectively observed a cohort of patients with Susac syndrome (SS), describing their clinical characteristics, diagnostic results, treatment regimens, and clinical course. The study found that most patients eventually developed the classical clinical triad during the disease course, and majority of the cases went into remission within two years. A detailed diagnostic workup and follow-up should be conducted for suspected SS patients to achieve a definite diagnosis.

JOURNAL OF CLINICAL MEDICINE (2022)

Letter Otorhinolaryngology

It is necessary to assess olfactory and gustatory function in post covid-19 patients, due to the omicron variant infection

Calixto Machado, Joel Gutierrez-Gil, Alina Gonzalez-Quevedo

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2023)

Article Clinical Neurology

Asymptomatic cerebral small vessel disease in adults with low cardiovascular risk

Zenaida Milagros Hernandez-Diaz, Marisol Pena-Sanchez, Mayelin Pimienta-Medina, Sergio Gonzalez-Garcia, Marta Brown Martinez, Marianela Arteche Prior, Yasmany Martin Arias, Edwin Humberto Hodelin-Maynard, Armando Abreu Duque, Alina Gonzalez-Quevedo

Summary: This study aimed to evaluate the relationship between cardiovascular risk calculated with the HEARTS app and cerebral small vessel disease (CSVD) burden in a population without cardio-cerebrovascular diseases, and estimate the prevalence of CSVD in low risk individuals. The results showed that CSVD was present even in individuals with low cardiovascular risk. Older age and arterial hypertension were independent predictors of the severity of CSVD.

BMJ NEUROLOGY OPEN (2023)

Article Clinical Neurology

Corticosteroid-induced low immunoglobulin levels in multiple sclerosis - A confounding factor

Mickael Bonnan, Henri Courtade, Stephane Debeugny

Summary: This study investigates the influence of disease-modifying drugs (DMD) and high-dose corticosteroids (CS) on immunoglobulin (Ig) levels in patients with multiple sclerosis (MS). The results demonstrate that CS infusion is strongly associated with a decrease in Ig levels during DMD treatment, suggesting the need for further studies considering the effect of CS on Ig levels.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Immunoglobulin levels are higher at multiple sclerosis onset - a part of natural history?

Mickael Bonnan, Henri Courtade, Stephane Debeugny

Summary: This study describes the natural history of Ig levels in multiple sclerosis (MS) patients. The results show that IgG levels were higher in samples taken before the onset of MS symptoms. Additionally, overall Ig levels remained stable during the first 1 to 20 years after onset.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

NMOSD-like and longitudinal extensive HTLV1-associated myelitis are extremes that flank an overlooked continuum

Mickael Bonnan, Stephane Olindo, Aissatou Signate, Quentin Lobjois, Maeva Stephant, Dalia Dimitri Boulos, Philippe Cabre

Summary: The study investigated the overlap between NMOSD features and HTLV1 infection, finding that acute onset of NMOSD-like HAM may be more common than expected and should be considered in high-risk patients. HTLV1 infection may lead to excessive inflammation of the targeted funiculi, resulting in extensive but often transient cord lesions. Some HAM cases demonstrate specific MRI lesions, and the most severe cases may mimic NMOSD attacks.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2021)

Article Clinical Neurology

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

Mickael Bonnan, Sylvie Ferrari, Henri Courtade, Paul Money, Pauline Desblache, Bruno Barroso, Stephane Debeugny

Summary: The study aimed to evaluate the safety and efficacy of intrathecal rituximab in progressive MS, with results showing no significant changes in clinical outcomes and biomarkers of inflammation, possibly due to its limited efficiency in the cerebrospinal fluid.

MULTIPLE SCLEROSIS INTERNATIONAL (2021)

No Data Available